




版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
DiseasesoftheStomachandDuodenumPARTIAnatomyPARTIIPepticUlcerDiseasePARTIIINeoplasmsGrossAnatomy:DivisionsofthestomachBloodsupplytothestomachandduodenumLymphaticdrainageofthestomachNerveofthestomachLeftvagusnerveAnteriorbranchesHepaticbranchesRightvagusnervePosteriorbranchCeliacbranchCrowfootcrowfootR.VagusL.VagusVagalinnervationofthestomachR.VagusVagalinnervationofthestomachGastricMorphologyCELLSLOCATIONFUNCTIONParietalBodySecretionofacidandintrinsicfactorMucusBody,AntrumMucusChiefBodyPepsinGAntrumGastrinDBody,antrumSomatostatinGastricCellTypes,Location,andFuction
CShapedLength:12fingers’breadthabout25cminadultD1SuperiorpartD2DescendingpartD3HorizontalpartD4AscendingpartGrossAnatomyoftheDuodenumPARTIAnatomyPARTIIPepticUlcerDiseasePARTIIINeoplasms1.HelicobacterpyloriInfection
1.
Productionoftoxicproductstocauselocaltissueinjury
2.
Inductionofalocalmucosalimmuneresponse
3.
IncreasedgastrinlevelswitharesultantincreaseinacidsecretionPathogenesisA:H.pyloriresidentonthegastricepithelium;B:Electronmicrograph2.Hypersecretionofgastricacid
“Noacid,noulcer”nowextendsto“ifacid,whyulcer”3.NonsteroidalAnti-inflammatoryDrugs4.MucosalinjuryMucus-bicarbonatelayerSurfaceepithelialcellsBloodflowtomucosaPathogenesisA:BalanceisgottenbetweenprotectiveandhostilefactorsB:BalanceisbrokenbetweenprotectiveandhostilefactorsClinicalPresentationGastriculcer
MadeworsebyeatingDuodenalUlcer
PossiblyworseatnightOccurs1-3hourspostprandialEpigastricpainHeartburnBelchingBloatedfeelingNauseaOthersymptomsDifferentialDiagnosisNeoplasmofthestomachPancreatitisPancreaticcancerDiverticulitisNonulcerdyspepsia(alsocalledfunctionaldyspepsia)CholecystitisGastritisComplicationsofPepticUlceri)Perforation&Penetration—intopancreas,liverandretroperitonealspaceii)PyloricObstructioniii)HemorrhageAcutePerforationA,Penetrationofagastriculcer;B,CrosssectionalviewofstomachwallandpancreasA,Endoscopicview;B,cross-sectionHemorrhagePyloricObstruction1.
Symptomsneedtoberelieved2.
Theulcerneedstobehealed3.
RecurrencemustbepreventedTheclinicianhasthreemajorgoalswhenfacedwithapatientwithulcerdisease:TherapySurgicalindicationsforPepticUlcerFourclassicindications
IntractabilityHemorrhagePerforation&PenetrationObstruction
Otherindications
StressulcerPancreatogeniculcerOnegoalofulcersurgeryistopreventgastricacidsecretionSurgicalProceduresforPepticUlcerGastrectomyTruncalvagotomySelectivevagotomyHighlyselectivevagotomyDistalGastrectomywithBillrothIAnastomosisDistalgastrectomywithBillrothIIanastomosisDistalgastrectomywithRoux-en-YanastomosisBillrothIIoperationandsomeofitsmodificationsV.EiselsbergGastrojejunostomy
1,TruncalVagotomy2,SelectiveVagotomy12HighlySelectiveVagotomySurgicalProceduresforPepticUlcerDrainageprocedureinassociationwithvagotomyPostgastrectomySyndromesDumpingSyndromeEarlyDumpingMetabolicDisturbancesAnemiadeficiencyinironimpairmentinvitaminB12metabolismImpairedabsorptionoffatdeficienciesincalciumOsteoporosisandosteomalaciaDumpingSyndromeEarlyDumpingMetabolicDisturbancesLateDumpingPostgastrectomySyndromesRelatedtoGastricReconstructionAfferentLoopSyndromeEfferentLoopObstructionAlkalineRefluxGastritisGastricAtonyCausesofafferentloopsyndromePostgastrectomySyndromesPostvagotomyDiarrheaPostvagotomySyndromesPostvagotomyDiarrheaPostvagotomyGastricAtonyIncompleteVagalTransectionSevereComplicationsofPepticUlceri)AcutePerforationii)MassiveHemorrhageiii)CicatricialPyloricstenosisDiagnosisandTreatmentforAcutePerforationClinicalPresentationofAcutePerforation
InitialsuddenonsetofsevereabdominalpainSyndromesPhysicalsignsi)Abdominaltendernessii)Abdominalreboundtendernessiii)Tabulateventeriv)BowelsoundsabsentFreeairX-rayCTscanFreeairInvestigationsInfectedascties
BileascitesDiagnosticeperitoneocentesisBUSAsctiesInvestigationsImmediatedifinitivesurgery:
i)Achroniculcerhistory;ii)Bleedingand/orobstrction;iii)WithoutpreoperativeriskforimmediatedifinitivesurgeryStandardtreatmentSimpleomentalpatchclosure:lifesavingoperationSurgicalManagementforPerforationSurgicalManagementforPerforationRepairofpepticulcerperforationLaparoscopicSurgeryNon-operativeManagementforPerforationSelectivetreatment
i)Intravenousflluids,ii)Nasogastricsuction,iii)BroadspectrumantibioticNoclinicalimprovementafter12h,requiredanoperationCarefullyselectedpaitents:
i)Age<70yearsoldii)Perforation<24hoursiii)Haemodynamicallystableiv)CanbecloselymonitoredClinicalpresention
i)Hematemesisii)Melenaorhematocheziaiii)Shock(Hemodynamicinstability:hypotensionwithsystolicbloodpressure<90mmHg)iv)AnemiaSevereComplication:
MassiveHemorrhageMassivehemorrhageEndoscopicimageABDigitalsubtractionangiography(DSA)NonoperativemanagementforMassiveHemorrhagei)Intravenousfluids(anitshocktherapy)ii)Nasogastricsuctioniii)Antiacid:protonpumpinhibitoriv)SomatostatinTherapeuticendoscopyInterventionalembolizationEndoscopiclasercoagulationEndoscopicsalineinjectionEndoscopichemostasiausingTitaniumClipVascularembolizationunderDSAIndicationsofOperativemanagementShockimmdeiatelyFailureofnonoperativemanagementBleeding>1000ml/24h,ahightransfusionrequirementAge>60yRebleedingafterstabilizationofrecentmassivehemorrhage
Co-existwithacuteperforationorcicatricialpyloricobstructionBleedingduringanti-ulcertherapySurgicalproceduresformassivebleedingi)Gastrectomy(involvingulcerlesion)iii)Bancroftplusarterysutures(gastroduodenalarteryorleftgastricartery)ii)Sewinghomeostasis+DrainageprocedureinassociationwithtruncalselectivevagotomyClinicalFeatures(1)HistoryofpreviouspepticulcersVomitting
volume:1000~2000mltime:recogniyablefood>8hpostprandialfeatures:projectilevomiting,devoidofanybile.SevereComplication:
Cicatricial
PyloricObstructionCicatricial
PyloricObstructionClinicalFeatures(2)
Physicalexamination
wasting,dehydrationperistalsis,splash-likesound
Laboratoryfeatures
MetabolicalkalosisBariumX-ray
aswollenstomachandnarrowedpylorusEndoscopy
cannotpassthroughthepylorusInvestigationsCicatricialPyloricObstructionCicatricialPyloricObstructionSurgicalproceduresforCicatricialPyloricObstruction1,Gastrectomy2,Drainageprocedureinassociationwithtruncalvagotomy3,Gastrojejunostomy
ClinicalfeaturesandmanagementoftheseverecomplicationsofpepticulcerOperativeindicationsforpepticulcerDifferentialdiagnosisofupperdigestivetracthemorrhageQUESTIONSPARTIAnatomyPARTIIPepticUlcerDiseasePARTIIINeoplasmsPARTIIINeoplasm1.Gastriccarcinoma2.Gastrointestinalstromaltumor3.Gastriclymphoma4.DuodenalcarcinomaEpidemiologyThefourth
mostcommoncancerworldwide,however,stomachcancerremainsthesecondmostcommoncauseofdeathfromcancerHigherratesinEasternAsia,SouthAmerica,EasternEuropeLowerratesinWesternEuropeandtheUnitedStates.GastriccarcinomaNutritional
LowfatorproteinconsumptionSaltedmeatorfishHighnitrateconsumptionHighcomplexcarbohydrateconsumptionCausesCausesEnvironmental
Poorfoodpreparation(smoked,salted)LackofrefrigerationPoordrinkingwaterSmokingMedical
PriorgastricsurgeryH.pyloriinfectionGastricatrophyandgastritisAdenomatouspolypsOther
MalegenderLowsocialclassCausesi)Earlygastriccancer(EGC)Gastriccancerconfinedtothemucosaorsubmucosa,regardlessofthepresenceorabsenceoflymphnodemetastasisPathologyii)Advancedgastriccancer(AGC)Cancercellsinfiltratetheproprialmusclelayerorserosa
EGCPathologyI:protrudedIIa:superficiallyelevatedIIc:superficiallydepressedIIb:superficiallyflatIII:excavatedEGC:EndoscopicimagesTypeIIITypeITypeIIPathologyBorrmann's
pathologicclassificationofgastriccancerbasedongrossappearanceAGC:Borrmann’sclassificationLinitisplasticaPhotomicrographsofGastricCarcinomaH&E,×400H&E,×25ArrowsonsignetringcellsTstageTstagearedefinedbydepthofpenetrationintothegastricwallLaminapropriaT1aT1bT4aT4bT3SubserosalconnectivetissueT1bT1aT4aT4bNStagingMetastesisDirectinvasionLyphmaticmetastesisHematogenousmetastasisSeedingmetastasisClinicalPresentationLacksspecificsymptomsearly:vagueepigastricdiscomfortindigestion.Epigastricpainisconstant,nonradiating,andunrelievedbyfoodingestion.Advanceddiseasemaypresentwithweightloss,anorexia,fatigue,orvomiting.Symptomsoftenreflectthesiteoforiginofthetumor.Proximaltumorsinvolvingthegastroesophagealjunctionoftenpresentwithdysphagia,whereasdistalantraltumorsmaypresentasgastricoutletobstruction.Hematemesis,anemic.Presentingaslargebowelobstruction.Physicalsignsi)apalpableabdominalmass,ii)apalpablesupraclavicular(Virchow's)orperiumbilical(SisterMaryJoseph's)lymphnode,ii)peritonealmetastasispalpablebyrectalexamination(Blummer'sshelf),iii)apalpableovarianmass(Krukenberg'stumor).iv)asthediseaseprogresses,jaundice,ascites,andcachexia.EndoscopyM-SCT(multipledetector-rowspiralCT)BUS&EUSDouble-contrastradiographyMRIDL(diagnosticlaparoscopy)PET-CTInvestigationsEndoscopyCarcinomainsituAdvancedcarcinomaNicheDouble-ContrastBariumUpperGIRadiographyEUSEUSTTNCTscan
ABCTNH1T4N2M1CTscan
MRITTLaparoscopyAbdominalmetastasisBUSleftrightLivermetastasisKrukenberg’stumorrightPET/CTT3N2Principlesofradicaloperationforgastriccanceri)Negativemarginii)Extentoflymphnodedissectioniii)Enblocresectioniv)M0SurgicalTreatmentforGastricCancerTreatmentforGastricCancerSurgeryEndoscopicmucosalresection(EMR)Endoscopicsubmucosaldissection(ESD)LaparoscopicSurgeryOpenSurgeryChemotherapyChemoradiotherapyTargettherapyEMRforEarliergastriccancer(EGC)CriteriaforEMRNCCN2013V2:1.TisorT1a2.Wellormoderatelydifferentiatedhistology3.Tumorslessthan15mminsize4.AbsenceofulcerationandnoevidenceofinvasivefindingCriteriaforEMRAbsoluteindication(EMR/ESD):DifferentiatedadenocarcinomaT1adiameteris≤2cmwithoutulcerfinding(UL-)JapaneseGastricCancerAssociationExpandedindication(ESD):TumorsclinicallydiagnosedasT1aand:(a)Differentiated,UL(-),but
>2cm(b)Differentiated-type,UL(+),and≤3cm(c)Undifferentiated-type,UL(-),and≤2cmEMREMREMR1.Difficulttoresectlargethan20mmtumorinsize2.DifficulttoresectulcerativelesionsLimitationofEMRtechniquesESDhasbeendevelopedESDforEGCESDESDLaparoscopicResection1)AsuitableprocedureforECG;2)TheefficacyandsafetyofthisapproachforadvancgastriccarcinomarequiresfurtherinvestigationOpenSurgeryforAdvancedGastricCancer1.AsuitableprocedureforACG2.R0resection3.R1resection4.R2resection
PrinciplesofradicaloperationforgastriccancerGastrectomywithregionallymphatics:perigastriclymphnodes(D1)andthosealongthenamedvesselsoftheceliacaxis(D2),withagoalofexamining15orgreaterlymphnodesGastrectomywithD2lymphadenectomyisthestandardtreatment
forcurablegastriccancerineasternAsia
GastrectomyandD2lymphadenectomyforadvancedgastriccarcinomaGastrectomyLymphadenectomyAnastomosisSubtotalgastrectomyRoux-en-YanastomosisBillrothIIanastomosisTotalgastrectomyLeftgastricAHepaticASplenicANo.11LNPORTALVEINAdjuvantTherapyChemotherapyRadiationTherapyTargetedTherapyECF:Epirubicin,Cisplatin,5-FuFOLFOX:Oxaliplatin,5-Fu,CFSOX:S-1,OxaliplatinXELOX:Capecitabin,OxaliplatinDCF:Docetaxel,Cisplatin,5-Fu……ChemotherapyPreoperativeChemotherapy
PostoperativeChemotherapyAfter3coursesofpreoperative
chemotherapyPreoperativechemotherapyLiverafterChemotherapyOurexperienceLaserrecannulizationandendoscopicdilationwithorwithoutstentplacementPalliativeTreatmentSurgicalpalliation
Resectionorbypassaloneorinconjunctionwithpercutaneous,endoscopic,orradiotherapytechniquesNonoperativetherapiesH.pyloriinfectionandgastriccarcinoma
Cyclooxygenase-2ActivationandgastriccarcinomaMini-invasiveoperationSentinelnodeNeoadjunctivechemotherapyMicrometastasis
IndividualizedtreatmentMolecularTargetedTherapiesCuttingedge:gastriccarcinoma
TargetedTherapiesAngiogenesisinhibitorBevacizumab(FDAapproved)ProteasomeinhibitorPS2341,bortezomib(FDAapproved)Growthfactorreceptor(EGFR),HERreceptorsinhibitorCetuximabEMD72000,matuzumabGefitinibErlotinibTrastuzumabCyclin-dependentkinaseinhibitor(CDKI)FlavopiridolGastrointestinalstromaltumor(GIST)MesenchymalneoplasmsLocatedprimarilyintheGItract,omentumandmesentery0.2%ofallGItumors80%ofGIsarcomas80%~90%stainpositiveforKITorPDGFREpidemiologyAmerica:10~20/1000,000peryearEurope:6.6~14.5/1000,000peryearHighestincidenceamonggroupaged50–65yearsSimilarmale/femaleincidence,althoughsomereportssuggesthigherincidenceinmenGISTlocationCausePresentationAbdominalpain,about50–70%GIbleeding,about50%NauseaandvomitingWeightlossPalpabletumormassesAnemiaInvestigationsEndoscopicUltrasound(US)ComputedTomography(CT)MagneticResonanceImaging(MRI)18F-FDGPositiveEmissionTomography(PET)DynamicContrast-EnhancedUltrasonography(DCE-US)BiopsyRisks:GISTsmaybesoftandfragileBiopsymaycausehemorrhageandincreasetheriskoftumordisseminationBiopsyisnecessaryif:Suspectinganothercancersuchaslymphoma
orgermcelltumorsConsideringneoadjuvanttherapyConfirmingmetastasisInvest
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025消防器材供應(yīng)合同
- 2025版知識產(chǎn)權(quán)許可合同模板
- 個人二手房買賣資金擔(dān)保合同
- 提升教學(xué)成果的組織化教研策略
- 水庫安全提升工程初步設(shè)計方案
- 科技創(chuàng)新中心項目發(fā)展前景分析報告
- 海水淡化行業(yè)發(fā)展趨勢與市場潛力分析
- 企業(yè)財務(wù)戰(zhàn)略調(diào)整的實施步驟計劃
- 分析優(yōu)勢的2025年國際金融理財師考試實證研究方法試題及答案
- 學(xué)校生物研究課程設(shè)置方案計劃
- 2025屆黑龍江省大慶市高三下學(xué)期第三次模擬考試歷史試題(含答案)
- 災(zāi)害自救互救與應(yīng)急逃生知識培訓(xùn)
- 養(yǎng)老院火災(zāi)事故防范重點培訓(xùn)課件
- 便秘的評估與護(hù)理
- 人才招聘中的社交媒體運用與效果評估
- 新能源電池材料回收行業(yè)深度調(diào)研及發(fā)展戰(zhàn)略咨詢報告
- 專題18 電磁感應(yīng)綜合題(解析版)-2025年高考物理二輪熱點題型歸納與變式演練(新高考)
- 北京海淀區(qū)2023-2024學(xué)年八年級下學(xué)期期中考試物理試題(原卷版)
- 煤礦汛期安全知識培訓(xùn)課件
- 安寧療護(hù)服務(wù)流程的質(zhì)量評估指標(biāo)
- 《玉米栽培技術(shù)與病蟲害防治》課件
評論
0/150
提交評論